Physician profile
Todd E Chontos
NPI 1619076247
$3,799.82
in general payments reported to CMS, 2019-2025
11 companies · $661 in 2025
The $661 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $91.29 · 2021: $85.62 · 2023: $335 · 2024: $2,292 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163 · Travel and Lodging: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,163.09 |
| Travel and Lodging | $1,124.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,411.60 | 2021-2025 | Precision7, Clareon, Eysuvis |
| Johnson & Johnson Vision Care, INC. | $431.80 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $364.81 | 2024 | |
| Lombart Brothers, INC. | $256.72 | 2019-2020 | |
| Coopervision INC. | $122.38 | 2023 | Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $80.91 | 2023 | Cequa |
| Shire North American Group INC | $45.54 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $31.95 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.68 | 2021 | |
| Bausch & Lomb Americas INC. | $17.81 | 2024 | Alden Scleral Zenlens |
| Novartis Pharmaceuticals Corporation | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Chontos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.